You must have heard about the Huntington’s treatment breakthrough made in a UCL lab!
A month ago, researchers in Professor Sarah Tabrizi's lab at Huntington's Disease Research Centre at UCL Queen Square Institute of Neurology, made national headlines with a groundbreaking gene therapy (AMT-130) that slowed Huntington’s disease progression by 75% in a Phase I/II clinical trial.
We’re beyond excited to welcome Dr Michael Murphy, Clinical Research Fellow and Specialty Registrar in Neurology, and a member of the Tabrizi lab, to give an exclusive talk about this remarkable study.
💡 What to expect:
- Learn how the therapy works and what makes it such a game-changer
- Explore the genetic mechanisms behind Huntington’s and how they were targeted
- Hear firsthand what it’s like working in a leading clinical neurology research team
- Ask questions about the trial, the research process, and life as a PhD student in medicin
Whether you're passionate about neuroscience, gene therapy, or just want to hear about one of UCL’s biggest research successes this year, don’t miss this opportunity to engage with someone directly involved in the discovery.
🍕 Snacks & refreshments provided
👉 GenSoc Paid Members Exclusive